Met inhibitors for enhancing radiotherapy efficacy

A method of treating a patient suffering from a tumor comprising administering to said patient a Met inhibitor, said Met inhibitor being selected from the group consisting of:

• i) an anti-Met monoclonal antibody,
• ii) a genetically engineered antibody comprising the complementarity determining regions (CDRs) of the anti-Met monoclonal antibody, and
• iii) a fragment of (i) or (ii) comprising the complementarity determining regions (CDRs) of the anti-Met monoclonal antibody, or combinations thereof,
• wherein said Met inhibitor is able to induce down-regulation of the receptor encoded by the MET gene and reduces and/or abrogates patient's resistance to radiotherapy.

A method of treating a patient suffering from a tumor comprising administering to said patient a nucleotide sequence encoding a Met inhibitor, said Met inhibitor being selected from the group consisting of:

• i) an anti-Met monoclonal antibody,
• ii) a genetically engineered antibody comprising the complementarity determining regions (CDRs) of the anti-Met monoclonal antibody, and
• iii) a fragment of (i) or (ii) comprising the complementarity determining regions (CDRs) of the anti-Met monoclonal antibody,
• wherein said Met inhibitor is able to induce down-regulation of the receptor encoded by the MET gene and reduces and/or abrogates patient's resistance to radiotherapy.